Aminosalicylic acid delayed-release granules - Jacobus Pharmaceutical/Lucane Pharma
Alternative Names: 4-Aminosalicylic acid - Lucane Pharma SA; Aminosalicylic acid delayed release granules - Jacobus Pharmaceutical/Lucane Pharma; GranuPAS; Para-aminosalicylic acid (PAS) - Lucane Pharma SA; Para-aminosalicylic acid gastro-resistant granules; PAS-GR; Paser; Paser granules - Jacobus Pharmaceutical/Lucane PharmaLatest Information Update: 30 Oct 2021
At a glance
- Originator Jacobus Pharmaceutical
- Developer Immedica; Jacobus Pharmaceutical; Lucane Pharma
- Class Anti-inflammatories; Antituberculars; Salicylates
- Mechanism of Action Dihydropteroate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Tuberculosis
Most Recent Events
- 29 Jan 2019 Aminosalicylic acid delayed-release granules is not yet available for Tuberculosis in Iceland, Liechtenstein and other countries in European Union (PO)
- 07 Nov 2018 Launched for Tuberculosis in Norway (PO)
- 17 Nov 2015 Launched for Tuberculosis in Finland (PO)